Mary Todd
Adult Health · Wagram, NCNPI 1326665142
Payments from drug & device makers
Across 109 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$508
- Novo Nordisk$420
- AstraZeneca$174
- Lilly USA, LLC$151
- Exact Sciences$143
- Mylan Specialty L.p.$50
- plus $248 from 11 others
What the payments were for
- Food & beverage$1,695100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $508 |
| Novo Nordisk | 35 | $420 |
| AstraZeneca | 10 | $174 |
| Lilly USA, LLC | 9 | $151 |
| Exact Sciences | 8 | $143 |
| Mylan Specialty L.p. | 3 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Merck | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Amgen | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$1,695 in reported general payments places this provider in the 75th percentile of 614 adult health providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $55,859 |
| FarxigaDapagliflozin Propanediol | 42 | $41,794 |
| JardianceEmpagliflozin | 23 | $20,659 |
| MounjaroTirzepatide | 16 | $17,053 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,858 |
| LinzessLinaclotide | 21 | $14,491 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,546 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,057 |
| Fluticasone Propionate | 36 | $991 |
| Gabapentin | 46 | $586 |
| Sumatriptan Succinate | 18 | $562 |
| Atorvastatin Calcium | 52 | $496 |
| Bupropion XlBupropion Hcl | 14 | $465 |
| Montelukast Sodium | 31 | $434 |
| Methylprednisolone | 66 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $420 | $55,85940 claims |
| AstraZenecaFarxiga | $174 | $41,79442 claims |
| Boehringer IngelheimJardiance | $40 | $20,65923 claims |
| Lilly USA, LLCMounjaro | $151 | $17,05316 claims |
| AbbVieLinzess | $508 | $14,49121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 adult health providers in North Carolina.
Other adult health in Wagram
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.